# Nordson Corporation (NDSN) Q3 2025 Financial Results Summary
Nordson Corporation (Nasdaq: NDSN) released its financial results for the third quarter of fiscal 2025 on August 18, 2025. Below is a summary of the key financial highlights and operational insights from the report.
### Third Quarter Highlights:
– **Sales**:
– Reported sales of **$742 million**, representing a **12% increase** year-over-year from **$662 million** in Q3 2024.
– Factors contributing to sales growth included:
– **8%** favorable impact from acquisitions.
– **2%** organic sales growth.
– **2%** contribution from currency translation.
– **Net Income**:
– Net income stood at **$126 million**, up from **$117 million** in the same quarter last year.
– **Earnings per diluted share** increased to **$2.22**, compared to **$2.04** in Q3 2024.
– **Adjusted Earnings**:
– Adjusted net income increased to **$155 million** (up **12%** from **$138 million** a year ago).
– Adjusted earnings per diluted share reached **$2.73**, marking a **13% increase** from **$2.41** in Q3 2024.
– **EBITDA**:
– EBITDA for the quarter was **$239 million**, or **32% of sales**, reflecting a **15% increase** compared to **$208 million** (or **31% of sales**) in the prior year.
– **Free Cash Flow**:
– Achieved a **free cash flow conversion of 180%** of net income.
– **Share Repurchase**:
– The Board of Directors authorized a new **$500 million share repurchase program**.
### Segment Performance:
1. **Industrial Precision Solutions**:
– Sales of **$351 million**, increased **1%** from**$348 million** last year.
– Organic sales decreased by **2%** but benefited from **3%** favorable currency translation.
– Operating profit rose to **$117 million**, a modest increase from **$115 million**.
2. **Medical and Fluid Solutions**:
– Sales surged by **32%** to **$219 million**, driven largely by a **31%** impact from acquisitions.
– Organic sales growth was flat, but increased by **4%** when excluding the medical contract manufacturing business.
– EBITDA grew significantly by **34%** to **$83 million** compared to the previous year.
3. **Advanced Technology Solutions**:
– Sales grew by **17%** to **$171 million**, including **15%** organic growth.
– Strong demand in electronics contributed to the organic sales increase.
– EBITDA of **$42 million**, an increase of **35%**, compared to **$31 million** a year ago.
### Financial Outlook:
– Backlog decreased by approximately **5%** sequentially, but the company affirms its previously stated full-year guidance for sales and earnings.
– Full year sales are tracking slightly below the mid-point of initial estimates, while adjusted earnings per share forecasts are slightly above the mid-point.
– The company anticipates that its ongoing initiatives, including product vitality enhancements and a responsive business model, will continue to drive organic growth amid dynamic market demand.
### Dividend Information:
– The report did not specify a new quarterly dividend declaration.
### Conclusion:
Nordson Corporation’s Q3 2025 results demonstrate notable growth in sales and adjusted earnings, robust EBITDA performance, and effective cash flow management, bolstered by strong contributions across segments, particularly in Medical and Fluid Solutions and Advanced Technology Solutions. The share repurchase authorization highlights management’s commitment to returning capital to shareholders in a strong operational performance context.
Here are the extracted tables in HTML format:
### CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
(Dollars in thousands except for per-share amounts)
| Three Months Ended | July 31, 2025 | July 31, 2024 | Nine Months Ended | July 31, 2025 | July 31, 2024 |
|---|---|---|---|---|---|
| Sales | $741,509 | $661,604 | $2,039,867 | $1,945,439 | |
| Cost of sales | $334,992 | $292,603 | $923,550 | $862,134 | |
| Gross profit | $406,517 | $369,001 | $1,116,317 | $1,083,305 | |
| Gross margin % | 54.8 % | 55.8 % | 54.7 % | 55.7 % | |
| Selling & administrative expenses | $206,539 | $201,943 | $606,642 | $588,196 | |
| Divestiture and related charges | $12,211 | $— | $12,211 | $— | |
| Operating profit | $187,767 | $167,058 | $497,464 | $495,109 | |
| Interest expense – net | -$25,698 | -$17,776 | -$77,335 | -$56,729 | |
| Other income (expense) – net | -$2,945 | $152 | -$5,380 | -$971 | |
| Income before income taxes | $159,124 | $149,434 | $414,749 | $437,409 | |
| Income taxes | $33,340 | $32,107 | $81,909 | $92,293 | |
| Net income | $125,784 | $117,327 | $332,840 | $345,116 | |
| Weighted-average common shares outstanding: | |||||
| Basic | $56,438 | $57,229 | $56,784 | $57,171 | |
| Diluted | $56,728 | $57,624 | $57,084 | $57,620 | |
| Earnings per share: | |||||
| Basic earnings | $2.23 | $2.05 | $5.86 | $6.04 | |
| Diluted earnings | $2.22 | $2.04 | $5.83 | $5.99 |
### CONSOLIDATED BALANCE SHEETS (Unaudited)
(Dollars in thousands)
| July 31, 2025 | October 31, 2024 | |
|---|---|---|
| Cash and cash equivalents | $147,788 | $115,952 |
| Receivables – net | $588,951 | $594,663 |
| Inventories – net | $459,251 | $476,935 |
| Other current assets | $91,275 | $87,482 |
| Assets held for sale | $39,583 | $— |
| Total current assets | $1,326,848 | $1,275,032 |
| Property, plant and equipment – net | $525,604 | $544,607 |
| Goodwill | $3,306,432 | $3,280,819 |
| Other assets | $850,829 | $900,508 |
| Total | $6,009,713 | $6,000,966 |
| Notes payable and debt due within one year | $336,078 | $103,928 |
| Accounts payable and accrued liabilities | $436,223 | $424,549 |
| Liabilities held for sale | $10,807 | $— |
| Total current liabilities | $783,108 | $528,477 |
| Long-term debt | $1,785,745 | $2,101,197 |
| Other liabilities | $459,075 | $439,100 |
| Total shareholders’ equity | $2,981,785 | $2,932,192 |
| Total | $6,009,713 | $6,000,966 |
